After Hours Summary: PHAS +36% on FDA Breakthrough Therapy designation news, ZGNX -32% after receiving FDA Refusal to File letter for FINTEPLAAfter Hours Gainers:
Companies trading higher in after hours in reaction to news: PHAS +36.4% (receives FDA Breakthrough Therapy designation for PB2452 for the reversal of the antiplatelet; provided immediate and sustained reversal of ticagrelor antiplatelet effects in ph I trial), CMRX +7.7% (appoints Mike Sherman as CEO and Mike Andriole as Chief Business Officer), GWPH +3.6% (competitor Zogenix [ZGNX] receives refusal to file letter for its seizure drug), AVYA +3.4% (continued strength on LBO speculation), HA +3.2% (reports March traffic +0.2%), MTSI +3.1% (still checking; is scheduled to present at Broadcasters conference April 8-11 where it will showcase portfolio of cable equalizers, cable drivers, reclockers and crosspoint switches supporting SDI)
After Hours Losers:
Companies trading lower in after hours in reaction to news: ZGNX -31.7% (receives Refusal to File Letter from FDA for FINTEPLA New Drug Application treating seizures associated with Dravet syndrome), MXWL -3.7% (indicated lower after Tesla [TSLA] extended the expiration to May 15 from April 10 of its previously announced tender offer to acquire outstanding common stock of Maxwell), NBEV -2.1% (after nearly 40% move higher on the day), CNCE -1.8% (following afternoon decline on decision from the Patent Trial and Appeal Board in IPR proceedings), MO -0.5% (provides update on FTC review of JUUL investment; continues to anticipate that theconversion of its JUUL shares will occur as planned)